The effects of a new aldose reductase inhibitor (tolrestat) in galactosemic and diabetic rats

Abstract

Tolrestat(N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine; AY-27,773; Alredase ®) is a potent, structurally novel inhibitor of aldose reductase (AR). In vitro, tolrestat inhibited in dose-dependent fashion the AR from bovine lenses (IC 50, 3.5 × 10 −8mol/L) and the formation of sorbitol in human RBC incubated with glucose (IC 50, 3 × 10 −8mol/L). Upon administration with the diet to rats made galactosemic or diabetic, tolrestat decreased, in a dose-related fashion, the accumulation of galactitol or sorbitol in the sciatic nerve and lens. The effectiveness of tolrestat depended upon the experimental conditions and tended to be higher in less severe galactosemia and after suitable pretreatment, particularly in galactosemic rats, resulting in ID 50 of 5 mg/kg/d in the sciatic nerve and 12–15 mg/kg/d in the lens. Tolrestat also decreased, in dose-related manner, the RBC sorbitol levels in normal and in streptozotocin diabetic rats; in the latter, at < 2 mg/kg/d, the RBC sorbitol was reduced to control levels.